Department of Chemistry, Hunter College of the City University of New York, New York, New York.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and.
J Nucl Med. 2019 Aug;60(8):1174-1182. doi: 10.2967/jnumed.118.223636. Epub 2019 Feb 7.
Antibodies are promising vectors for PET imaging. However, the high uptake of radioimmunoconjugates in nontarget tissues such as the liver and spleen hampers their performance as radiotracers. This off-target uptake can lead to suboptimal tumor-to-background activity concentration ratios, decreasing the contrast of images and reducing their diagnostic utility. A possible cause of this uptake is the sequestration of radioimmunoconjugates by immune cells bearing Fc-γ-receptors (FcγR) that bind to the Fc regions of antibodies. Since the heavy chain glycans influence the affinity of FcγR for the Fc domain, we set out to investigate whether radioimmunoconjugates with truncated glycans would exhibit altered binding to FcγRI and, in turn, improved in vivo performance. Using the HER2-targeting antibody trastuzumab, we synthesized a series of desferrioxamine-bearing immunoconjugates with differing glycosylation states and interrogated their FcγRI binding via surface plasmon resonance, enzyme-linked immunosorbent assay, and flow cytometry. Furthermore, we labeled these immunoconjugates with Zr and explored their biodistribution in athymic nude, NSG, and humanized NSG mice bearing human epidermal growth factor receptor 2-expressing human breast cancer xenografts. We observed a strong correlation between the impaired in vitro FcγRI binding of deglycosylated immunoconjugates and significant decreases in the in vivo off-target uptake of the corresponding Zr-labeled radioimmunoconjugates (i.e., liver activity concentrations are reduced by ∼3.5-fold in humanized NSG mice). These reductions in off-target uptake were accompanied by concomitant increases in the tumoral activity concentrations of the glycoengineered radioimmunoconjugates, ultimately yielding improved tumor-to-healthy organ contrast and higher quality PET images. Our findings suggest that the deglycosylation of antibodies represents a facile strategy for improving the quality of immuno-PET in animal models as well as in certain patient populations.
抗体是 PET 成像有前途的载体。然而,放射性免疫偶联物在肝脏和脾脏等非靶组织中的高摄取率阻碍了它们作为放射性示踪剂的性能。这种非靶组织摄取会导致肿瘤与背景的活性浓度比值不理想,降低图像对比度,降低其诊断效用。这种摄取的一个可能原因是免疫细胞通过结合抗体的 Fc 区的 Fc-γ 受体(FcγR)隔离放射性免疫偶联物。由于重链糖基影响 FcγR 对 Fc 结构域的亲和力,我们着手研究具有截断糖基的放射性免疫偶联物是否会表现出对 FcγRI 的结合改变,进而改善体内性能。使用 HER2 靶向抗体曲妥珠单抗,我们合成了一系列具有不同糖基化状态的带有去铁胺的免疫偶联物,并通过表面等离子体共振、酶联免疫吸附试验和流式细胞术研究了它们与 FcγRI 的结合。此外,我们用 Zr 标记这些免疫偶联物,并研究了它们在荷有人表皮生长因子受体 2 表达的人乳腺癌异种移植瘤的无胸腺裸鼠、NSG 和人源化 NSG 小鼠中的生物分布。我们观察到,去糖基化免疫偶联物体外 FcγRI 结合能力受损与相应 Zr 标记放射性免疫偶联物体内非靶组织摄取显著减少之间存在很强的相关性(即在人源化 NSG 小鼠中,肝脏活性浓度降低了约 3.5 倍)。这种非靶组织摄取的减少伴随着糖基工程放射性免疫偶联物肿瘤活性浓度的同时增加,最终产生了更好的肿瘤与健康器官对比度和更高质量的 PET 图像。我们的研究结果表明,抗体去糖基化是提高动物模型和某些患者人群中免疫 PET 质量的一种简单策略。